Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
PRME Stock Chart & Stats
$5.38
-$0.14(-4.27%)
At close: 4:00 PM EST
$5.38
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$1.11 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)4.10M
Market Cap
$910.58M
Enterprise Value$337.08M
Total Cash (Recent Filing)$98.34M
Total Debt (Recent Filing)$119.74M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Oct 31, 2025EPS Estimate
-0.25Last Dividend Ex-Date
Sep 10, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding178,196,010
10 Day Avg. Volume4,246,582
30 Day Avg. Volume4,102,687
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue67.95
Enterprise Value/Gross Profit108.84
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$6.00Price Target Upside11.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Financial HealthThe net proceeds from the offering were approximately $138.2M, which meaningfully strengthened the company's balance sheet and removed its near-term financial overhang.
Funding And InvestmentsThe Cystic Fibrosis Foundation committed up to $24 million in additional funding to accelerate the development of prime editors for Cystic Fibrosis.
Technological AdvancementsPRME's preclinical data and prime editing technology show promise, reflected by the 90% editing efficiency in the 2nd patient treated ex vivo.
Bears Say
Earnings PerformancePrime reported collaboration revenue of $1.1M and a net loss of $0.41 per share, compared to the consensus estimates of $4.2M and a net loss of $0.35 per share.
Market PerceptionNeutral rating on PRME is maintained without a price target due to the lack of near-term meaningful catalysts and legal uncertainty.
Product Development TimelinePrime is expected to remain a preclinical-stage company for the near term, with no clinical data expected until 2027.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $1.11 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $910.58M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Oct 31, 2025 which is in 6 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.351 by -$0.059.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 178,196,010 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.351. Following the earnings report the stock price went down -9.582%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (11.52% Upside)
$6.00 (11.52% Upside)
Blogger Sentiment
Neutral
PRME Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $34.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.83%
12-Months-Change
Fundamentals
Return on Equity
-154.81%
Trailing 12-Months
Asset Growth
7.43%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$6.00
▲(11.52% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
49.88% Insiders
5.56% Mutual Funds
0.22% Other Institutional Investors
35.77% Public Companies and
Individual Investors